Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use

Diabetes Educator

Volumn 35, Issue 1, 2009, Pages 136-146

  Rubin, Richard R ^a,c   Peyrot, Mark ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MARYLAND   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60049101477     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721708326989     Document Type: Article

References (24)

1. Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development and labeling claims. Washington, DC: FDA.
2. Marra G., DIAB. &TE.S S Study Group. The DIAB. & TE.S Project: how patients perceive diabetes and diabetes therapy. Acta Biomed. 2004 ; 75: 164-170.
3. Ware JH, Sherbourne CD The MOS 36-Item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 ; 30: 473-483.
4. Boyer JG, Earp JL The development of an instrument for assessing the quality of life of people with diabetes. Med Care. 1997 ; 35: 440-453.
5. Bradley C, ed. Handbook of Psychology and Diabetes: a Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers ; 1994.
6. Charpentier G., Fleury F., Dubroca I., Vaur L., Clerson P. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab. 2005 ; 31: 189-195.
7. Kelley K., Dempsey C. An evaluation of an insulin transfer programme delivered in a group setting. J Clin Nurs. 2007 ; 16: 152-158.
8. Tahrani AA, Digwood S., Lee C., Moulilk P. Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service. Int J Clin Pract. 2007 ; 61: 329-335.
9. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 1999 ; 2: 113-127.
10. Peyrot M., Rubin RR Assessing health-related quality of life (HRQOL): The Insulin Delivery System Rating Questionnaire (IDSRQ). Diabetes Care. 2005 ; 28: 53-58.
11. SYMLIN [package insert]. San Diego, CA. Amylin Pharmaceuticals 2005.
12. Whitehouse F., Kruger DF, Fineman MS, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002 ; 25: 724-730.
13. Ratner RE, Dickey R., Fineman MS, et al. Amylin replacement with pramlintide as adjunct to insulin therapy improves long-term glycemic and weight control in type 1 diabetes mellitus: a one-year randomized controlled trial. Diabetes Med. 2004 ; 21: 1204-1212.
14. Hollander PA, Levy P., Fineman MS, et al. Pramlinitide therapy as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 ; 26: 784-790.
15. Levetan C., Want LL, Weyer C., et al. Impact of pramlintide on glucose fluctuations, postprandial glucose, glucagons, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003 ; 26: 1-8.
16. Weyer C., Gottlieb A., Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes. Diabetes Care. 2003 ; 26: 3074-3079.
17. Chapman I., Parker B., Doran S., et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005 ; 48: 838-848.
18. Edelman S., Garg S., Frias J., et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 ; 29: 2189-2195.
19. Riddle M., Frias J., Zhang B., et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007 ; 30: 2794-2799.
20. Rubin RR, Peyrot M. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. Curr Med Res Opin. 2007 ; 23: 1919-1929.
21. Marrero DG, Crean J., Zhang B., et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007 ; 30: 210-216.
22. Faul F., Erdfelder E., Lang AG Power 3: a flexible statistical power analysis program for social, behavioral, and biomedical sciences. Behav Res Methods. 2007 ; 39: 175-191.
23. Norman GR, Sloan JA, Wyrwich KW Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003 ; 41: 582-592.
24. Bradley C. Diabetes Treatment Satisfaction Questionnaire: change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care. 1999 ; 22: 530-532.